New York, NY -- (SBWIRE) -- 01/10/2018 -- Burkitt lymphoma is a rare disease and occurs only in one in every 30-50 people with non-Hodgkin's lymphomas. According to the World Health Organization (WHO), Burkitt lymphomas are of three types, namely, endemic, sporadic and immunodeficiency associated. Endemic NHL is also known as African type and affects African children aged between 4 to 7 years; this type of Burkitt lymphoma is closely associated with the Epstein-Barr virus (EBV), the main cause of glandular fever. Sporadic type occurs worldwide especially in western region. According to WebMD, in the United States and Western Europe, it accounts for up to 40% of all pediatric lymphoma cases. Immunodeficiency associated type of Burkitt lymphoma is more common in people with HIV/AIDS. Burkitt lymphoma is characterized by swelling of the lymph nodes in the neck, groin or under the arm which is often painless. This condition is more common in men than women.

Request Report For TOC @ https://www.persistencemarketresearch.com/toc/21130

It is one of the fastest growing lymphomas and becomes fatal if left untreated. Intensive chemotherapy has been proven to be successful in long term survival of more than half the people with this condition. Prednisone, cyclophosphamide, ifosfamide, vincristine, cytarabine, doxorubicin, methotrexate, and etoposide are the most commonly used medicines during chemotherapy. Geographically, North America leads the market for Burkitt lymphoma therapeutics owing to factors such as well-established reimbursement scenario in the region and significant number of Burkitt lymphoma cases diagnosed each year. According to WebMD, in the United States, around 1,200 new cases are diagnosed each year. Africa represents a potential market for Burkitt lymphoma therapeutics, however, poor economy of the region may hamper the market growth to some extent.

Request to Sample of Report @ https://www.persistencemarketresearch.com/samples/21130

Takeda Pharmaceutical Company Limited, Novartis AG, Seattle Genetics, Inc., Sanofi, Mayo Clinic, MethylGene Inc., Eisai Inc. and Cellerant Therapeutics, Inc. are some major players and research laboratories among others engaged in the development, manufacturing and marketing of therapeutic agents used to treat Burkitt lymphoma.

Pre Book Full Report @ https://www.persistencemarketresearch.com/checkout/21130

About Persistence Market Research
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.

PMR stands committed to bringing more accuracy and speed to clients' business decisions. From ready-to-purchase market research reports to customized research solutions, PMR's engagement models are highly flexible without compromising on its deep-seated research values.